肉芽肿伴多发性血管炎
IIf公司
显微镜下多血管炎
医学
PTX3型
抗体
自身抗体
嗜酸性
抗中性粒细胞胞浆抗体
血管炎
潘卡
免疫学
胃肠病学
内科学
病理
系统性血管炎
生物标志物
炎症
疾病
生物
生物化学
作者
Roberto Padoan,Mariele Gatto,Anna Ghirardello,Marta Tonello,Chiara Franco,Mara Felicetti,Franco Schiavon,Andrea Doria
标识
DOI:10.1016/j.jaut.2021.102725
摘要
To investigate prevalence of anti-Pentraxin 3 (PTX3) antibodies in sera of anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) patients. Anti-PTX3 and PTX3 levels were analysed by enzyme-linked immunosorbent assays in sera from unselected patients with AAV and compared with patients with systemic lupus erythematosus (SLE, n = 130), other connective tissue diseases (CTDs, n = 97) and matched healthy controls (n = 97). Optical density (OD) cut-off for positive anti-PTX3 antibodies was determined by ROC curve analysis and set as 0.234. Indirect immunofluorescence (IIF) on fixed human granulocytes was used to analyze the fluorescence pattern of anti-PTX3 antibodies. Liquid-phase inhibition tests were conducted to assess potential interferences. We included 101 AAV patients (females 58%, median age 60[51–69] years) affected either with granulomatosis with polyangiitis (GPA, n = 51), microscopic polyangiitis (MPA, n = 12) or eosinophilic granulomatosis with polyangiitis (EGPA, n = 38). Anti-PTX3 antibodies were detected in 29.7% AAV patients, being significantly higher than in healthy controls (p < 0.001) and CTDs (p = 0.030) but lower than in SLE (p = 0.004). Anti-PTX3 antibody prevalence was 44.7% in EGPA, 25% in MPA and 19% in GPA (p = 0.034). Among ANCA negative patients, 35.7% displayed positive anti-PTX3 antibodies. Anti-PTX3 were associated with a lower prevalence of systemic (p = 0.002), ear-nose-throat (p = 0.006) and renal manifestations (p = 0.016). Anti-PTX3 antibodies were characterized by a specific IIF pattern on fixed granulocytes. PTX3 serum levels resulted lower in AAV than healthy controls (p < 0.001). PTX3 inhibited anti-PTX3 binding in a dose-dependent manner. Anti-PTX3 autoantibodies appear a promising novel biomarker of AAV, especially EGPA.
科研通智能强力驱动
Strongly Powered by AbleSci AI